MX358117B - Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer. - Google Patents
Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer.Info
- Publication number
- MX358117B MX358117B MX2014000116A MX2014000116A MX358117B MX 358117 B MX358117 B MX 358117B MX 2014000116 A MX2014000116 A MX 2014000116A MX 2014000116 A MX2014000116 A MX 2014000116A MX 358117 B MX358117 B MX 358117B
- Authority
- MX
- Mexico
- Prior art keywords
- prognosis
- determining
- nucleic acids
- methods
- cancer subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Abstract
La presente invención se refiere a un método in vitro para (i) determinar el pronóstico de un sujeto de cáncer de colon o colorrectal, después de una cirugía o resección para remover el tumor primario y antes del tratamiento posterior a la cirugía a resección del tumor primario, (ii) determinar la necesidad de tratamiento médico adicional para un sujeto con cáncer de colon o colorrectal después del tratamiento para remover el tumor primario y antes del tratamiento posterior a la cirugía o resección de un tumor y antes del tratamiento posterior a la cirugía o resección, (iii) seleccionar a un sujeto con cáncer de colon o colorrectal para un tratamiento adicional para el cáncer después del tratamiento para remover el tumor primario y antes del tratamiento posterior a la cirugía o resección, o (iv) determinar, después de un tratamiento para remover el tumor primario y antes del tratamiento posterior a la cirugía o resección, si el cáncer de colon o colorrectal de un sujeto de cáncer es metastásico, caracterizado porque comprende los pasos de: a. medir el nivel de ADN genómico metilado de Septin9 (SEC ID NO: 1) o RASSF2a (SEC ID NO: 16) o un fragmento de los mismos, que está metilado en cáncer de color o cáncer colorrectal, pero que no está metilado en tejido no canceroso, en una muestra de sangra obtenida de un sujeto antes de remover el tumor primario por cirugía o resección (muestra previa a un tratamiento); b. medir el nivel de ADN genómico metilado de Septin9 (SEC ID NO: 1) o RASSF2a (SEC ID NO: 16) o un fragmento de los mismos, que está metilado en cáncer de color o cáncer colorrectal, pero que no está metilado en tejido no canceroso, en una muestra de sangre obtenida de un sujeto después de remover el tumor primario por cirugía o resección y antes de un tratamiento posterior a la cirugía o resección del tumor primario (muestra posterior a un tratamiento), con lo cual una cantidad aumentada lo equivalente del ADN genómico metilado o fragmento en la muestra posterior a un tratamiento, después de la remoción del tumor primario, en comparación con la muestra previa a un tratamiento, indica (i) un mal diagnóstico, (ii) la necesidad de un tratamiento adicional para el cáncer en el sujeto, (iii) seleccionar al sujeto para un tratamiento adicional para el cáncer, o (iv) que el cáncer es metastásico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505919P | 2011-07-08 | 2011-07-08 | |
| PCT/EP2012/063436 WO2013007702A1 (en) | 2011-07-08 | 2012-07-09 | Methods and nucleic acids for determining the prognosis of a cancer subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000116A MX2014000116A (es) | 2014-03-27 |
| MX358117B true MX358117B (es) | 2018-08-06 |
Family
ID=46458553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000116A MX358117B (es) | 2011-07-08 | 2012-07-09 | Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10626462B2 (es) |
| EP (1) | EP2729579B1 (es) |
| JP (1) | JP6397762B2 (es) |
| KR (1) | KR102046668B1 (es) |
| CN (2) | CN108048573A (es) |
| AU (1) | AU2012282528B2 (es) |
| BR (1) | BR112014000443B1 (es) |
| CA (1) | CA2840149C (es) |
| DK (1) | DK2729579T3 (es) |
| EA (1) | EA034232B1 (es) |
| ES (1) | ES2654561T3 (es) |
| HR (1) | HRP20180001T1 (es) |
| HU (1) | HUE036036T2 (es) |
| IL (1) | IL230303B (es) |
| LT (1) | LT2729579T (es) |
| MX (1) | MX358117B (es) |
| NO (1) | NO2729579T3 (es) |
| SI (1) | SI2729579T1 (es) |
| WO (1) | WO2013007702A1 (es) |
| ZA (1) | ZA201400089B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732390B2 (en) | 2012-09-20 | 2017-08-15 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| US10706957B2 (en) | 2012-09-20 | 2020-07-07 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of tumor from plasma |
| CA2951141C (en) * | 2014-06-04 | 2021-11-30 | Quest Diagnostics Investments Incorporated | Methylated markers for colorectal cancer |
| CN104745575B (zh) | 2014-08-08 | 2019-03-12 | 博诚研究中心 | 用于检测细胞增殖性异常或疾病程度分级的基因组合物及其用途 |
| CN115181802A (zh) * | 2015-04-23 | 2022-10-14 | 博尔诚（北京）科技有限公司 | 一种检测Septin9基因甲基化的试剂盒及其应用 |
| WO2017009322A1 (en) * | 2015-07-15 | 2017-01-19 | Universiteit Gent | Probes and a methylation in situ hybridization assay |
| JP6897970B2 (ja) * | 2015-09-08 | 2021-07-07 | 国立大学法人山口大学 | 大腸腫瘍の有無を検査する方法 |
| CN109804086B (zh) | 2016-08-10 | 2023-06-13 | 格里尔公司 | 制备双标签dna库用于亚硫酸盐转化定序的方法 |
| US11965157B2 (en) | 2017-04-19 | 2024-04-23 | Singlera Genomics, Inc. | Compositions and methods for library construction and sequence analysis |
| CN107385056A (zh) * | 2017-08-10 | 2017-11-24 | 上海时代基因医学科技有限公司 | 一种检测SEPT9基因不同Cpg岛甲基化的试剂盒及应用 |
| WO2019076949A1 (en) * | 2017-10-18 | 2019-04-25 | Deutsches Krebsforschungszentrum | MEANS AND METHODS FOR CLASSIFYING COLORECTAL CANCERS |
| US20200370126A1 (en) * | 2017-11-29 | 2020-11-26 | The Regents Of The University Of Michigan | Compositions and methods for characterizing cancer |
| CN108796080B (zh) * | 2018-06-06 | 2022-06-07 | 苏州唯善生物科技有限公司 | 用于结直肠癌诊断、检测或筛查的引物和探针组 |
| CN109055552A (zh) * | 2018-08-23 | 2018-12-21 | 北京迈基诺基因科技股份有限公司 | 检测Septin9基因启动子是否甲基化的方法及其专用成套试剂 |
| CN112195243A (zh) * | 2020-09-22 | 2021-01-08 | 北京华大吉比爱生物技术有限公司 | 一种检测多基因甲基化的试剂盒及其应用 |
| KR102404750B1 (ko) * | 2021-10-14 | 2022-06-07 | 주식회사 엔도믹스 | 세포 유리 dna를 이용한 대장암 진단을 위한 메틸화 마커 유전자 및 이의 용도 |
| CN114561452A (zh) * | 2022-03-10 | 2022-05-31 | 天津市人民医院 | mSEPT9作为预测结直肠癌患者术后复发风险标志物及用于评价化疗方案有效性的应用 |
| KR102559496B1 (ko) * | 2022-04-26 | 2023-07-25 | 연세대학교 산학협력단 | 핵산의 메틸화 여부 확인용 조성물 및 핵산의 메틸화 여부를 확인하는 방법 |
| CN115029462B (zh) * | 2022-08-10 | 2022-11-08 | 中国农业科学院农业质量标准与检测技术研究所 | 一种动植物疫病的核酸标准物质、形貌模拟方法及其应用 |
| WO2024064369A1 (en) * | 2022-09-23 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods for amplifying nucleic acids |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US150000A (en) | 1874-04-21 | Improvement in cigar mouth - pieces | ||
| US412900A (en) | 1889-10-15 | roaers | ||
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| US6184211B1 (en) | 1993-11-30 | 2001-02-06 | Methylgene Inc. | Inhibition of DNA methyltransferase |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5514758A (en) | 1994-09-30 | 1996-05-07 | The Goodyear Tire & Rubber Company | Process for making latex for high performance masking tape |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6251594B1 (en) | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US7700324B1 (en) | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| CN1150317C (zh) * | 1999-08-10 | 2004-05-19 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
| AU2002224328A1 (en) * | 2000-09-20 | 2002-04-02 | Case Western Reserve University | Methods and compositions for detecting cancers associated with methylation of hmlh1promoter dna |
| DE10112515B4 (de) | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| CN1187456C (zh) * | 2001-11-27 | 2005-02-02 | 暨南大学 | CpG岛甲基化检测试剂盒及其应用 |
| WO2005059172A2 (en) | 2003-12-11 | 2005-06-30 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| DE10348407A1 (de) * | 2003-10-17 | 2005-05-19 | Widschwendter, Martin, Prof. | Prognostische und diagnostische Marker für Zell-proliferative Erkrankungen von Brustgeweben |
| JP4765058B2 (ja) | 2004-12-13 | 2011-09-07 | 国立大学法人 岡山大学 | 核酸修飾前の検体の前処理方法 |
| SG183708A1 (en) * | 2005-04-15 | 2012-09-27 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| WO2007085497A2 (en) | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Markers for the prediction of outcome of anthracycline treatment |
| WO2007118704A2 (en) * | 2006-04-17 | 2007-10-25 | Epigenomics Ag | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
| US9939441B2 (en) * | 2006-07-21 | 2018-04-10 | Epigenomics Ag | Methods and nucleic acids for analyses for cellular proliferative disorders |
| WO2008100913A2 (en) * | 2007-02-12 | 2008-08-21 | The Johns Hopkins University | Early detection and prognosis of colon cancers |
| JP5378687B2 (ja) | 2007-03-02 | 2013-12-25 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｓｐ１遺伝子および／またはｓｒｄ５ａ２遺伝子中のメチル化シトシンを利用する、肝臓癌、肝臓癌発症リスク、肝臓癌再発リスク、肝臓癌悪性度および肝臓癌の経時的進展の検出方法 |
| US20110177511A1 (en) | 2008-09-19 | 2011-07-21 | Noriaki Yamamoto | Method for determining breast cancer metastasis and method for evaluating serum |
| WO2010065916A1 (en) | 2008-12-04 | 2010-06-10 | Rush University Medical Center | Dna methylation based test for monitoring efficacy of treatment |
| EP2309005B1 (en) | 2009-08-03 | 2015-03-04 | Epigenomics AG | Methods for preservation of genomic DNA sequence complexity |
-
2012
- 2012-07-09 MX MX2014000116A patent/MX358117B/es active IP Right Grant
- 2012-07-09 CN CN201810020458.1A patent/CN108048573A/zh active Pending
- 2012-07-09 NO NO12732686A patent/NO2729579T3/no unknown
- 2012-07-09 US US14/131,445 patent/US10626462B2/en active Active
- 2012-07-09 ES ES12732686.6T patent/ES2654561T3/es active Active
- 2012-07-09 BR BR112014000443-9A patent/BR112014000443B1/pt active IP Right Grant
- 2012-07-09 KR KR1020147003119A patent/KR102046668B1/ko active IP Right Grant
- 2012-07-09 EP EP12732686.6A patent/EP2729579B1/en active Active
- 2012-07-09 CN CN201280033813.XA patent/CN103732759A/zh active Pending
- 2012-07-09 HU HUE12732686A patent/HUE036036T2/hu unknown
- 2012-07-09 CA CA2840149A patent/CA2840149C/en active Active
- 2012-07-09 SI SI201231155T patent/SI2729579T1/en unknown
- 2012-07-09 AU AU2012282528A patent/AU2012282528B2/en active Active
- 2012-07-09 JP JP2014517844A patent/JP6397762B2/ja active Active
- 2012-07-09 EA EA201400117A patent/EA034232B1/ru not_active IP Right Cessation
- 2012-07-09 WO PCT/EP2012/063436 patent/WO2013007702A1/en active Application Filing
- 2012-07-09 LT LTEP12732686.6T patent/LT2729579T/lt unknown
- 2012-07-09 DK DK12732686.6T patent/DK2729579T3/en active
-
2014
- 2014-01-02 IL IL230303A patent/IL230303B/en active IP Right Grant
- 2014-01-06 ZA ZA2014/00089A patent/ZA201400089B/en unknown
-
2018
- 2018-01-02 HR HRP20180001TT patent/HRP20180001T1/hr unknown
-
2020
- 2020-03-10 US US16/814,321 patent/US11261499B2/en active Active
-
2022
- 2022-01-18 US US17/577,836 patent/US20220243277A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220243277A1 (en) | 2022-08-04 |
| CN103732759A (zh) | 2014-04-16 |
| LT2729579T (lt) | 2018-02-26 |
| HUE036036T2 (hu) | 2018-06-28 |
| MX2014000116A (es) | 2014-03-27 |
| BR112014000443A2 (pt) | 2017-02-14 |
| IL230303B (en) | 2018-05-31 |
| ES2654561T3 (es) | 2018-02-14 |
| CA2840149C (en) | 2021-10-26 |
| BR112014000443B1 (pt) | 2021-03-23 |
| US20150031021A1 (en) | 2015-01-29 |
| HRP20180001T1 (hr) | 2018-03-09 |
| EA034232B1 (ru) | 2020-01-20 |
| SI2729579T1 (en) | 2018-07-31 |
| EA201400117A1 (ru) | 2014-06-30 |
| JP2014520520A (ja) | 2014-08-25 |
| EP2729579A1 (en) | 2014-05-14 |
| KR102046668B1 (ko) | 2019-11-19 |
| NO2729579T3 (es) | 2018-03-03 |
| WO2013007702A1 (en) | 2013-01-17 |
| EP2729579B1 (en) | 2017-10-04 |
| JP6397762B2 (ja) | 2018-09-26 |
| US11261499B2 (en) | 2022-03-01 |
| US20200308656A1 (en) | 2020-10-01 |
| DK2729579T3 (en) | 2018-01-08 |
| KR20140044385A (ko) | 2014-04-14 |
| CA2840149A1 (en) | 2013-01-17 |
| US10626462B2 (en) | 2020-04-21 |
| AU2012282528A1 (en) | 2014-01-23 |
| CN108048573A (zh) | 2018-05-18 |
| AU2012282528B2 (en) | 2017-04-13 |
| ZA201400089B (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000116A (es) | Metodos y acidos nucleicos para determinar el pronostico de un sujeto con cancer. | |
| AU2019229353A1 (en) | Mutant calreticulin for the diagnosis of myeloid malignancies | |
| IL233548A (en) | Nucleic Acids Methods for Diagnosing Irregularities in Cell Development | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| AU2015318823A1 (en) | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor | |
| EP2576837A4 (en) | CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER | |
| MX2013000917A (es) | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| EP2611941A4 (en) | GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS | |
| WO2010135692A3 (en) | Mirna biomarkers of prostate disease | |
| AU2011260390A8 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| WO2012083969A3 (en) | Microrna for diagnosis of pancreatic cancer | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| EP2723866A4 (en) | METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES | |
| WO2009074328A3 (en) | Methods and nucleic acids for analyses of lung carcinoma | |
| EP4202441A3 (en) | Gene expression profile in macrophages for the diagnosis of cancer | |
| WO2010007083A3 (en) | Methods and nucleic acids for analyses of cell proliferative disorders | |
| EP3385717A3 (en) | Methods of detecting prostate cancer | |
| EP3693742A3 (en) | Methods of detecting prostate cancer | |
| PL2444811T3 (pl) | Sposoby diagnozowania lub prognozowania raka jelita grubego | |
| WO2009092597A3 (en) | Methods and nucleic acids for analyses of prostate cancer | |
| WO2009065511A3 (en) | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders | |
| TW201144809A (en) | Marker for gastric cancer and method for detecting gastric cancer | |
| WO2013132354A3 (en) | Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer | |
| WO2013040358A3 (en) | Assays and compositions for detection of agr2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |